Autolus Therapeutics will announce Q4 2025 financial results on March 27, 2026, followed by a conference call.
Quiver AI Summary
Autolus Therapeutics plc, a biopharmaceutical company focused on next-generation programmed T cell therapies, announced it will release its fourth quarter and full year 2025 financial results on March 27, 2026, before U.S. market opening. A conference call and webcast hosted by management will follow at 8:30 am EDT to discuss these results and provide a business update. Participants must pre-register to obtain dial-in details. Autolus is known for its engineered T cell therapies aimed at treating cancer and autoimmune diseases, including its marketed product AUCATZYL® and various candidates under development. More information is available on their website.
Potential Positives
- Autolus Therapeutics is scheduled to release its 2025 financial results, indicating a clear communication strategy with investors and stakeholders about its financial performance.
- The upcoming conference call and webcast provide an opportunity for management to discuss operational highlights, which may enhance transparency and investor confidence in the company's progress and future prospects.
- Autolus continues to operate as a commercial-stage biopharmaceutical company, showcasing its established market presence with products like AUCATZYL® and an innovative pipeline addressing significant medical needs.
- The focus on next-generation T cell therapies reinforces Autolus's commitment to advancing cancer and autoimmune disease treatments, positioning the company at the forefront of biopharmaceutical innovation.
Potential Negatives
- Announcement of upcoming financial results may indicate that the company has not yet achieved significant business milestones or improvements in performance to communicate proactively.
- The specific mention of pre-registration for the conference call might signal a low expectation of attendance or engagement among stakeholders, which could reflect negatively on the company's current reputation.
- The reliance on proprietary technologies in therapy development could raise concerns about potential challenges in scalability or efficacy compared to competing therapies in the market.
FAQ
When will Autolus Therapeutics release its financial results for 2025?
Autolus Therapeutics will release its financial results on March 27, 2026, before U.S. markets open.
What time is the conference call for discussing financial results?
The conference call will take place at 8:30am EDT / 12:30pm GMT on March 27, 2026.
How can I access the conference call for Autolus Therapeutics?
Participants should pre-register to receive dial-in numbers and a personal PIN for the conference call.
Where can I find the audio webcast of the conference call?
The audio webcast will be available on the events section of Autolus’ website.
What does Autolus Therapeutics specialize in?
Autolus Therapeutics focuses on developing next-generation T cell therapies for cancer and autoimmune diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AUTL Hedge Fund Activity
We have seen 37 institutional investors add shares of $AUTL stock to their portfolio, and 57 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP removed 27,147,035 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $44,249,667
- FMR LLC removed 7,105,585 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $11,582,103
- CITADEL ADVISORS LLC removed 4,884,452 shares (-80.8%) from their portfolio in Q4 2025, for an estimated $9,720,059
- MAK CAPITAL ONE LLC added 3,987,727 shares (+15.3%) to their portfolio in Q4 2025, for an estimated $7,935,576
- BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. added 3,361,156 shares (+inf%) to their portfolio in Q4 2025, for an estimated $6,688,700
- AXA S.A. removed 3,126,167 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $5,095,652
- PRICE T ROWE ASSOCIATES INC /MD/ removed 2,694,202 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $4,391,549
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$AUTL Analyst Ratings
Wall Street analysts have issued reports on $AUTL in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 01/12/2026
To track analyst ratings and price targets for $AUTL, check out Quiver Quantitative's $AUTL forecast page.
$AUTL Price Targets
Multiple analysts have issued price targets for $AUTL recently. We have seen 2 analysts offer price targets for $AUTL in the last 6 months, with a median target of $9.5.
Here are some recent targets:
- Emily Bodnar from HC Wainwright & Co. set a target price of $9.0 on 02/17/2026
- Gil Blum from Needham set a target price of $10.0 on 01/12/2026
Full Release
LONDON and GAITHERSBURG, Md., March 16, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its fourth quarter and full year 2025 financial results and operational highlights before open of U.S. markets on Friday, March 27, 2026.
Management will host a conference call and webcast at 8:30am EDT / 12:30pm GMT to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.
A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL
®
, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit
www.autolus.com
.
Contact:
Amanda Cray
+1 617-967-0207
[email protected]
